Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

RespireRx collaborates with University College London to study treatment options for GRIA disorders

RespireRx Pharmaceuticals

RespireRx Pharmaceuticals chief scientific officer Arnold Lippa joins Proactive's Natalie Stoberman to share details of the company's latest collaboration with University College London to study the use of AMPAkines for the treatment of GRIA disorders. GRIA Disorder refers to a family of rare genetic diseases caused by mutations in the AMPA glutamate receptor genes that cause either a loss or gain in the functioning of these receptors, which are the site of action of RespireRx’s AMPAkines and which play an important role in learning and memory as well as other critical biological functions. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

April 21, 2023 10:52 AM Eastern Daylight Time

Video

Tiziana Life Sciences plans to file Investigational New Drug Application for Alzheimer's treatment

Tiziana Life Sciences PLC

Tiziana Life Sciences chief medical officer Dr Matthew Davis joins Proactive's Natalie Stoberman to share how the company is planning to file an Investigational New Drug (IND) application for intranasal foralumab as a treatment of Alzheimer's disease. Dr Davis says there are no FDA-approved treatments for Alzheimer’s disease specific to neuroinflammation. He adds that the goal is to study three months' administration of intranasal foralumab in Alzheimer’s disease patients to see if neuroinflammatory-activated microglia will return to the baseline homeostatic state. The IND also includes seeking $3 million in non-dilutive funding from a prestigious Alzheimer’s foundation to support the Phase 2a trial. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

April 21, 2023 10:47 AM Eastern Daylight Time

Video

Keep Your Little Ones Happy & Healthy This Spring

YourUpdateTV

Having a picky eater can be increasingly frustrating and lead to feelings of guilt for many parents who are already experiencing immense pressure to ensure their kids are getting the right nutrients at mealtime.. Recently, SmartyPants Vitamins’ CEO, Brenda Demers, participated in a satellite media tour campaign to share insights on how to manage kids at mealtime and the role that multivitamins play in getting necessary nutrients. A video accompanying this announcement is available at: https://youtu.be/LGOB_yq8N9E For many parents, making sure their family gets the nutrients they need to stay healthy can be a constant struggle - especially if there are picky eaters in the house! Not to mention, with the vitamin market being as crowded as it is, knowing where to dig in can be daunting at times. Top it all off with trying to find a brand that also provides options that support the whole family, and you might be left paralyzed by indecision. As the best vitamin brand for parents of picky eaters, SmartyPants is industry-leading in the comprehensiveness of its formulations, transparency, and efficacy - with 30+ Clean Label Project® certified products that are non-GMO and contain zero synthetic colors. For its most innovative launch to-date, SmartyPants Vitamins announced new SmartyPants Sugar Free Multi & Omegas gummy multivitamins in Kids, Women’s, and Prenatal formats. Unlike other sugar free gummy multivitamins, SmartyPants’ new Sugar Free Multi & Omegas don’t use sugar alcohols. All SmartyPants products are non-GMO and third-party lab tested for purity, potency and safety. More information on the new products can be found below: ● SmartyPants Sugar Free Kids Multi & Omegas is a sugar free premium all-in-one multi and omega-3 for children's developmental years*. It is thoughtfully formulated with 16 nutrients in delicious sugar free strawberry banana-flavored gummies.* ○ SmartyPants Kids Sleep is also now available as a sugar free supplement with melatonin, that helps your children fall asleep and stay asleep for longer, in just 1 gummy.* It is formulated for children 4 years and older. ● SmartyPants Sugar Free Women’s Multi & Omegas is a sugar free premium all-in-one multi and omega-3 for daily nutrition support*. It is thoughtfully formulated with 19 nutrients in delicious sugar-free orange-flavored gummies.* ● SmartyPants Sugar Free Prenatal Multi & Omegas is a sugar free premium all-in-one multi and omega-3 to support the health of mom and baby*. It is thoughtfully formulated with 19 nutrients in delicious sugar free lemon-flavored gummies.* SmartyPants Sugar Free Multi & Omegas come as an additional option for daily nutrition support alongside the brand’s portfolio of delicious gummies for every life stage and dietary need – including organic and vegetarian options – to products that target functional needs such as immunity, sleep, and more. SmartyPants’ Sugar Free line is now available on Amazon and will be available on Target.com and in select Target locations. For more information about SmartyPants visit smartypantsvitamins.com ------------------------------------------------------ *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. BIO Brenda Demers is the CEO of SmartyPants Vitamins, where she most recently led SmartyPants' integration into Unilever's Health & Wellbeing collective. Prior to joining SmartyPants, Brenda spent more than 23 years leading businesses across the Beauty, Personal Care, Food, OTC Pharmaceuticals, and Vitamins, Minerals & Supplements categories globally. Brenda, her husband, and their children currently live in Los Angeles, where they are avid sports fans and enjoy spending weekends exploring the beauty of their new home. ABOUT SMARTYPANTS VITAMINS Founded in 2011, SmartyPants Vitamins is a purpose-led supplement brand on a mission to simplify health for families without sacrificing quality. As the best vitamin brand for kids, SmartyPants supplements are formulated with premium nutrients and high-quality ingredients—and a delicious taste and texture that appeals to picky eaters. All SmartyPants supplements are third-party lab tested for purity, potency and safety. From its inception, SmartyPants has generated life-changing nutrient donations for women and children in the U.S. and globally via the brand’s partnership with Vitamin Angels. To learn more, visit smartypantsvitamins.com or check out @smartypants on Instagram. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

April 21, 2023 09:20 AM Eastern Daylight Time

Video

Rodedawg International Industries, Inc. (OTC: RWGI) Expands into the Licensed California Cannabis Market

Rodedawg International Industries, Inc.

McapMediaWire -- Rodedawg International Industries, Inc. (OTC: RWGI ) proudly announces the expansion into the California licensed cannabis market. “We are proud to announce to our shareholders that Rodedawg has signed an agreement with Chron Industries, LLC for the expansion into the California licensed market, which will expedite the growth in revenue streams with offerings and distribution outlets. Given that today is 4/20, we wanted to share the great news that we have accomplished a major milestone in our operations. This agreement gives the company the ability to operate with a licensed company and gives Year 1 the forward acceleration toward our goal of $7 million plus in revenues for 2023. We believe that the revenue figure could be much higher but we want to stay with conservative Year 1 revenue targets. Chron Industries, LLC is a fully operational, revenue producing California licensed cannabis company and the exact opportunity that allows our company the expansion yet saves our shareholders millions of dollars.” states Chris Swartz, CEO of Rodedawg Intl. Ind., Inc. Chris Swartz, CEO, adds, “According to Statista, sales of legal cannabis in California reach 5.3 billion U.S. dollars in 2022. This value was over twice as high as 2018. This is a massive market and this agreement positions the company to jointly provide Cannabis related products and services with revenue streams back to the Rodedawg enterprise. In the coming weeks, the company will be providing updates on the agreement. Additionally, we will also be announcing the company’s entrance into providing a wide range of health care products and multi-faceted distribution sales channels.” Mr. Swartz concludes, “In the next few weeks, management will further inform shareholders on the timeframe and progress of accomplishing success milestones to further expand shareholder value. Behind the scenes, we are lining up additional acquisitions, cancellation of shares, and completion of our audit, as our plan from the beginning has been positioning the Company for significant growth leading to uplisting.” About Rodedawg International Industries, Inc. Rodedawg International Industries, Inc. (OTC: RWGI) is focused on providing management services, acquisitions and restructuring resources throughout the regulated California cannabis market. We are a trusted partner and asset to licensed cultivation, distributors, manufacturers, and retail dispensaries. Please note the company Twitter address is https://twitter.com/RWGImerger for regular updates. About Budding Horizon, LLC Budding Horizon, LLC is a California Limited Liability Company with offices in Orange County, California. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets. The company website is https://buddinghorizon.com/ Contact Information: Rodedawg International Industries, Inc. 1-800-793-0355 ir@buddinghorizon.com Safe Harbor Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements. SOURCE: Rodedawg International Industries, Inc. Contact Details Rodedawg International Industries, Inc ir@buddinghorizon.com

April 20, 2023 09:30 AM Eastern Daylight Time

News Release

Freedom Holdings Embarks on New Business Focus

FREEDOM HLDG INC.

McapMediaWire -- Freedom Holdings, Inc. aka Freedom Acquisition Corp (OTC: FHLD) (“FHLD” or the "Company”), is pleased to announce new management has completed its first purchase agreement evidencing the Company’s commitment to the new business focus in the Cannabis industry. The Company has entered into a Binding Stock Exchange Agreement with Village Flora, Inc., a California Corporation. The Agreement calls for: Freedom to purchase 100% of Village Flora, Inc. with the issuance Freedom 200,000 common shares @ $2.00 per share for a total of $400,000.00 in value. Villa Flora shall become a wholly owned subsidiary of Freedom. Village Flora holds two fully up to date Cannabis Licenses, with an estimated worth of $1.5 Million. As a wholly owned subsidiary of Freedom the Licenses will become an asset of the company. License #1 – Delivery Service License #2 – Supports the oil extraction process that will be used to promote the Company’s medical research. The Company is also happy to announce further that it has entered negotiations with additional cannabis related companies to acquire and merge under the freedom umbrella. We look forward to continuing to grow the business plan and building shareholder value. Press Release Contact: John Vivian CEO Freedom Holdings, Inc. 813-699-4098 Safe Harbor Statement This press release contains statements which may constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of the Company, members of its management, and assumptions on which such statements are based. We caution prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Contact Details Freedom Holdings, Inc. +1 813-699-4098

April 20, 2023 09:00 AM Eastern Daylight Time

Luxury Meets Cannabis Conference (LMCC) Spring 2023 Edition Returns To Hudson Yards, NYC: May 18 & 19

LMCC Ventures LLC

The Luxury Meets Cannabis Conference (LMCC) today announced its first wave of speakers, retail attendees, and showcasing brands for its Spring 2023 Edition, which returns to Hudson Yards in New York City on May 18 & 19, 2023. Launched in 2018 as a first-of-its-kind B2B event, LMCC has grown into the go-to biannual venue for product discovery and extensive education, connecting visionary CBD and Cannabis wellness, beauty, food/beverage, and lifestyle accessories brands – and their founders – to a powerful combination of hundreds of traditional retail buyers, luxe dispensaries, editorial press, and investors from around the world. 2023: The Year of the Brand “We’ve reimagined the boutique trade show experience by providing an immersive luxury retail environment for our business attendees to discover the finest wellness, beauty, and food & beverage brands in the space,” said LMCC’s Co-Founder & Executive Director Jed Wexler. “And as Cannabis retail comes alive in New York, 2023 truly is ‘The Year of the Brand’ with LMCC being the bridge to a massive new, elevated mainstream CPG wellness category.” In a testament to the mainstreaming of the category, LMCC will welcome a robust roster of industry leaders for two full days of panel discussions – each moderated by a veritable who’s who in media. Speakers: Jacques Tortoroli, CEO, Charlotte’s Web (“The Official CBD of Major League Baseball”) Jake Bullock, Co-Founder & CEO, Cann Tremaine Wright, Cannabis Control Board Chair, New York Office of Cannabis Management Arana Hankin-Biggers, President, Union Square Travel Agency Emily Schildt, Founder & CEO, Pop Up Grocer Amir Zwickel, Founder, SHOWFIELDS Melany Dobson, CEO, Hudson Cannabis & Ben Dobson, President, Hudson Cannabis Media: Tiffany Kary, Bloomberg News Chala June, Contributor, Bon Appétit Brian Underwood, Women’s Health Michael Kusek & Brit Smith, Different Leaf Kelly Kovack, Founder & CEO, BeautyMatter Oset Babür-Winter, Food & Wine Claire McCormack, Beauty Independent Erica La Sala, Beauty Independent Jeremy Berke (‘Cannabis Business Reporter of the Year”) Recently named one of BeautyMatter’s “Top Global Wellness & Beauty Trade Events” and Trade Show Executive Magazine’s “Leading Upcoming Trade Events in North America,” LMCC will present its signature Brand Showcase Studio — a pre-vetted, store-ready exhibition throughout the two-day program featuring keynotes and conversations with speakers, founders, and journalists. The LMCC 2023 Spring Edition will welcome hundreds of buyers from A-tier retail outlets, 50 accepted showcasing brands, 50 industry-leading speakers, and close to 900 global business attendees. Indicating the excitement and opportunity surrounding New York’s just-opened legal Cannabis market, LMCC is slated to host its largest and most impactful event to date. Exclusive New York and National Brand Launches at LMCC Spring 2023 From Charlotte’s Web and the re-rise of CBD wellness to Hudson Cannabis, 1906, Rose Los Angeles, Drew Martin, Dad Grass, PAMOS, and a slew of pioneering New York Cannabis brand launches exclusively during the show, LMCC presents the world’s finest store-ready product portfolios in and outside of the space. View the LMCC Spring 2023 peaker schedule and Brand Showcase Studio line-up at lmccshow.com. Follow LMCC Instagram or LinkedIn. LMCC SPRING 2023 BRAND SHOWCASE STUDIO DIRECTORY Brands can still apply to activate their brands at LMCC Spring 2023 HERE. View the latest Brand Showcase Studio directory HERE. LMCC SPRING 2023 RETAIL BUYER PREVIEW Admission is complimentary only for qualified retail buyers and their teams. Register representatives from traditional/online retailers, hotels/spas, independent wellness boutiques, luxe dispensaries, natural markets, and more HERE. ### Attendee Tickets: Two-day, all-access passes to LMCC Spring 2023 are $695. Purchase passes HERE. About LMCC: Founded in 2018, LMCC Ventures LLC is the parent company of the annual Luxury Meets Cannabis Conference (LMCC) in New York City. LMCC is the premier B2B event connecting A-tier retailers, media, investors, leading dispensaries, and CPG executives to premium CBD, hemp and Cannabis brands — with a keen focus on beauty, wellness, food & beverage. Past participants include retailers like Sephora, Nordstrom, Credo Beauty, and Bloomingdale’s; media including The New York Times, Glossy, Travel & Leisure, O, The Oprah Magazine, and Robb Report; and speakers from Mitch Baruchowitz (Merida Capital Holdings) and Cindy Capobianco (Lord Jones) to Bobbi Brown and Frederic Fekkai. Guidelines & Legal: Cannabis in name only; No smoking or vaping on any kind permitted inside the venue; Illegal products will NOT be allowed on-site Local laws strictly apply. Badge or Pass Required: LMCC is an invite-only B2B trade event not open to the public. A badge or pass is required. Contact Details LMCC Press Katie Shapiro +1 303-882-5596 katie@katieshapiromedia.com Company Website https://www.lmccshow.com/

April 20, 2023 06:30 AM Eastern Daylight Time

ANGLE PLC has opened up "a major market opportunity" with breast cancer partnership

ANGLE PLC

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Thomas Warner from Proactive after announcing a development partnership with BioView. The partnership will see the two firms develop to create a circulating tumour cell (CTC) HER2 assay for breast cancer that could ultimately enable hospitals worldwide to access technology that measures HER2 status in breast cancer patients. Newlands says it has opened up "a major market opportunity" with the partnership. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 20, 2023 04:20 AM Eastern Daylight Time

Video

AVRA Medical Robotics Announces Closing of Merger with CardioVentures

SS Innovations International Inc

McapMediaWire -- AVRA Medical Robotics, Inc. (“the Company”) (OTC: AVMRD ), a medical robotics software and artificial intelligence company, announced that it has closed on its previously announced acquisition by merger of CardioVentures, Inc. The Company also announced that in connection with the closing of the merger, the Company changed its corporate name to SS Innovations International, Inc. (“SSII”), implemented a one-for-ten reverse stock split (the “Reverse Split”), effective April 17, 2023, and underwent certain management changes. CardioVentures, through a subsidiary, owns a controlling interest in Sudhir Srivastava Innovations Pvt. Ltd., an Indian private limited company (“ SSI - India ”). Based in Haryana, India, SSI-India is engaged in the business of developing innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSI Mantra” surgical robotic system and a wide range of surgical instruments capable of supporting a variety of cardiac and other surgical procedures. The Company now intends to focus on the business of SSI-India and has plans to globally expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. https://ssinnovations.com In the merger, holders of the outstanding shares of common stock of CardioVentures (including certain parties who provided interim convertible financing during the pendency of the merger, were issued shares of SSII common stock representing approximately 95% of issued and outstanding shares of SSII post-merger common stock, with the existing shareholders of SSII holding 5% of issued and outstanding shares of SSII common stock post-merger. At closing of the merger, the holders of CardioVentures common stock also received shares of newly designated Series A Non-Convertible Preferred Stock, which entitles them to voting control of the Company. The Company’s common stock began trading on a post-Reverse Split basis at the opening of trading on Monday April 17, 2023. In connection therewith, the Company's ticker symbol will be AMVRD for twenty (20) trading days commencing April 17, 2023, to designate that it is trading on a post-Reverse Split basis. In addition, our post-Reverse Split common stock will trade under the new CUSIP Number 05453U203. As a result of the Reverse Split, every ten pre-Reverse Split shares of common stock outstanding automatically combined into one new share of post-Reverse Split common stock without any action on the part of the holders. The Reverse Split also applies to shares of common stock issuable upon the conversion of outstanding warrants and stock options. No fractional shares will be issued as a result of the Reverse Split. Any fractional shares resulting from the Reverse Split will be rounded up to the nearest whole share on a per shareholder basis. The Company expects that shareholders holding our shares at registered brokerage firms or at the transfer agent will have the Reverse Split transaction processed automatically in their accounts over the next few days. Shareholders holding physical stock certificates may request new certificates evidencing their post-Reverse Split shares by contacting the Company’s transfer agent, VStock Transfer LLC, at info@vstocktransfer.com or (212) 828-8436. The Company announced changes to its management team. At closing of merger, Alen Sands York and Ettore Tomasetti resigned as directors of the Company and Barry F. Cohen, Dr. Ray Powers and Dr. Farhan Taghizadeh resigned as Chief Executive Officer and Acting Chief Financial Officer, Chief Operating Officer, and Chief Medical Officer of the Company, respectively. Mr. Cohen continues as a director of the Company and assumed the office of Chief Operating Officer – Americas. In addition, Dr. Sudhir Srivastava became a director, Chairman and Chief Executive Officer of SSII, Dr. Vishwajyoti P. Srivastava, the son of Dr. Sudhir Srivastava became a director and President and Chief Operating Officer – South Asia and Anup Sethi became Chief Financial Officer of the Company. For further information and details regarding all of the above matters, please see the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission contemporaneously with the issuance of this release. The Report may be viewed at the SEC’s website, www.sec.gov. About SS Innovations International, Inc. SS Innovations International, Inc. (OTC: AVMRD ) is engaged in the business of developing innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSI Mantra” surgical robotic system and a wide range of surgical instruments capable of supporting a variety of surgical procedures including cardiac. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at www.ssinnovations.com Forward-Looking Statements This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. For Further Information Contact: Barry F. Cohen bcohen@avramedical.com Contact Details Barry F. Cohen bcohen@avramedical.com

April 19, 2023 04:58 PM Eastern Daylight Time

Dear America, Mission Possible: Prevention and Cures Starts Now

The American Center for Cures

I hope this letter finds you and your family in good health. The exceptional leadership and resilience of this nation has been an inspiration to Dr. Rick Boxer and me, prompting us to embark on a vital mission that resonates with every American, regardless of wealth, race, or political affiliation: combating disease. Despite our nation's efforts, we have not achieved the level of prevention and cures necessary to alleviate the suffering and burden of diseases that affect us all. It is time for a paradigm shift, and we believe that every American is in a unique position to help drive this transformation. The American Center for Cures, which we co-founded, aims to establish a fully funded private-sector mission dedicated to preventing and curing the most devastating diseases, such as Alzheimer's, Parkinson's, various forms of cancer, heart disease, diabetes, and all other diseases including orphan diseases. Our vision is to assemble the most successful CEOs in America to lead individual centers focused on these diseases, with each center receiving $36 billion in funding. By combining resources, leadership, focus, and a sense of urgency, we believe we can create a new era in disease prevention and cures. This effort has the potential to be the most significant legacy issue of our lifetimes, impacting not only American families but also the global community. We humbly request Corporate America’s public endorsement and the social support of the American People to provide hope to millions and promote a business-like model of accountability that is currently lacking. Furthermore, we encourage you to urge every member of Congress and the White House to expedite their support for this initiative. We are not merely asking for their backing; we are insisting on it. This mission is for you, your children, and future generations. It is likely that you and your loved ones have been personally affected by a disease that should no longer exist. By embracing this mantle of leadership today, we can make a lasting impact on the lives of countless individuals. Former Secretary of Health Tom Price has stated that the American Center for Cures could rival the greatest achievements in American history. My partner, Dr. Rick Boxer, was recently appointed to the National Cancer Advisory Board by President Biden. We need your voice and skills now more than ever. We commend the extraordinary work of researchers around the world and their commitment to delivering cures. However, a systemic issue exists within the medical use authorization and approval process, and it delays getting cures into the hands of the people who need them now. We’re on the cusp of curing pancreatic, breast, and brain cancer, as well as preventing heart attacks but the current model, because of economic- and process -related obstacles, does not accommodate success. The American Center for Cures is offering a solution to this problem by providing a mission, funding, responsibility, accountability, and leadership, will fundamentally restructure and speed the process of working with the FDA and all relevant parties for authorized cures. Just like the speed of getting the COVID vaccine approved and authorized for use, American Center for Cures is committed to bringing new cures and treatments to patients as quickly and efficiently as possible. We believe that now is the time to harness our global technological advances to establish a process and urgency that will bring these pieces together for the betterment of humanity. By acting today, we can create a lasting legacy in the fight against disease. We are Unity Strong! Best regards, Lou Weisbach Co-founder, The American Center for Cures About American Center for Cures The American Center for Cures (ACC) initiative is a fully funded mission to prevent, treat or cure diseases that plague every American family. The initiative will be funded by the sale of $750B bonds by the Federal Reserve, providing the capital needed to accelerate the current trajectory of medicine. Annual interest will be paid through the licensing of new compounds and drugs to pharmaceutical companies. The principal will be repaid by savings provided to the United States Government through successes in the areas of prevention and cures. The ACC business model will cost the government and taxpayers nothing, making this the single most impactful investment on behalf of the American people in the nation’s history. For more information, please visit https://theamericancenterforcures.org. Contact Details Rainier Communications Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://theamericancenterforcures.org

April 19, 2023 01:33 PM Eastern Daylight Time

1 ... 107 108 109 110 111 ... 245